Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928272 · ClinicalTrials.gov registry record · Phase 3
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
A Phase 3 study of Long COVID, sponsored by Douglas D. Fraser.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
- 8
- Study locations
NCT06928272 is a Phase 3 study of Long COVID that is actively recruiting participants, run by Douglas D. Fraser. The registered enrollment target is 348 participants, below the 2,181-participant average among 50 other Long COVID trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT06928272, a Phase 3 study of Long COVID, is actively recruiting participants, sponsored by Douglas D. Fraser.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
- 8
- Study locations
Study Summary
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.
Conditions Studied
Interventions
- DRUG Upadacitinib
- DRUG Pirfenidone
- DRUG Placebo for pirfenidone
- DRUG Placebo for upadacitinib
Study Locations (8)
Quebec
- Institut de Recherches Cliniques de Montréal (IRCM) - Montreal
- Centre de Recherche du CHUS (CRCHUS) - Sherbrooke
Roma
- INMI Lazzaro Spallanzani IRCCS - Roma
- Sapienza Università di Roma - Roma
California
- Laura Rodriguez Research Institute - San Diego
Rio de Janerio
- Ini-Fiocruz - Rio de Janeiro
Kampala
- Joint Clinical Research Centre (JCRC) - Kampala
Lusaka Province
- University Teaching Hospital - Lusaka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06928272
The ClinicalTrials.gov registry entry for NCT06928272 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,181-participant average among 50 other Long COVID trials with a reported enrollment target (84% lower). The listed sponsor is Douglas D. Fraser, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 4 interventions - of which Upadacitinib is the first listed.
NCT06928272 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Quebec, Roma, California.
Frequently Asked Questions
What is clinical trial NCT06928272 about?
NCT06928272 is a clinical study titled "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study". The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three m...
What is the current status of trial NCT06928272?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2025-09-10. Estimated completion is 2027-12.
What conditions does trial NCT06928272 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT06928272?
The interventions under investigation include: Upadacitinib (DRUG), Pirfenidone (DRUG), Placebo for pirfenidone (DRUG), Placebo for upadacitinib (DRUG).
Who is sponsoring clinical trial NCT06928272?
This trial is sponsored by Douglas D. Fraser, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928272 being conducted?
This trial has 8 study locations across California, Rio de Janerio, Quebec, Roma, Kampala. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Sauna for Long Covid
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.